IL6 and rheumatoid arthritis: Treatment of RA and PsA has been revolutionised by the implementation of aggressive treatment strategies such as Treat to Target, the introduction of Early Inflammatory Arthritis Clinics and the availability of therapies directed against soluble mediators (TNF inhibitors and IL6 blockers), immune cells (B cells) and intracellular signalling pathways (JAK inhibitors) [149].